NCT03510390View on ClinicalTrials.gov

Metformin in Head and Neck Squamous Cell Carcinoma: Effect on Tissue Oxygenation

NACompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

June 13, 2018

Primary Completion Date

September 15, 2021

Study Completion Date

November 15, 2021

Conditions
Head and Neck CancerOral Cavity Squamous Cell Carcinoma
Interventions
DRUG

Metformin

850 mg, oral, twice daily, 9-14 days

Trial Locations (1)

3010

Inselspital, Bern University Hospital, Bern

All Listed Sponsors
collaborator

University of Bern

OTHER

collaborator

Werner und Hedy Berger-Janser - Stiftung

UNKNOWN

lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT03510390 - Metformin in Head and Neck Squamous Cell Carcinoma: Effect on Tissue Oxygenation | Biotech Hunter | Biotech Hunter